Pancreatic Cancer Research

Clinical trialPhase 2Active not recruiting

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

1911GCCC: Open Label, Phase 2 Trial of Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy

NCT04098081↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Ongoing
Phase
Phase 2
Status
Active not recruiting
Study type
Interventional
Start
12 December 2019
Expected end
31 December 2026
Enrollment
15 participants
Sites
1
Primary outcomes
response rate
Sponsor
Other
Results posted
No
Last update
1 July 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 7